Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 4/2015

Open Access 01-04-2015 | Neurological Update

Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions

Authors: James Varley, Angela Vincent, Sarosh R. Irani

Published in: Journal of Neurology | Issue 4/2015

Login to get access

Abstract

The field of neuronal surface-directed antibody-mediated diseases of the central nervous system has dramatically expanded in the last few years and now forms an important cluster of treatable neurological conditions. In this review, we focus on three areas. First, we review the demographics, clinical features and treatment responses of these conditions. Second, we consider their pathophysiology and compare autoantibody mechanisms and their effects to genetic or pharmacological disruptions of the target antigens. Third, we discuss areas of controversy within the field, propose possible resolutions, and explore new directions for neuronal surface antibody-mediated diseases.
Literature
1.
2.
McKeon A, Pittock SJ (2011) Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 122(4):381–400PubMedCrossRef
3.
Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE et al (2007) Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61(1):25–36PubMedCentralPubMedCrossRef
4.
Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P et al (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133(9):2734–2748PubMedCentralPubMedCrossRef
5.
Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165PubMedCentralPubMedCrossRef
6.
Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA (2012) The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 54(7):899–904PubMedCentralPubMedCrossRef
7.
Irani SR, Bera K, Waters P, Zuliani L, Maxwell S et al (2010) N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133(Pt 6):1655–1667PubMedCentralPubMedCrossRef
8.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098PubMedCentralPubMedCrossRef
9.
Florance NR, Davis RL, Lam C, Szperka C, Zhou L et al (2009) Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 66(1):11–18PubMedCentralPubMedCrossRef
10.
11.
Niehusmann P, Dalmau J, Rudlowski C, Vincent A, Elger CE et al (2009) Diagnostic value of N-methyl-d-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 66(4):458–464PubMedCrossRef
12.
13.
Cobo-Calvo A, Izquierdo Gracia C, Quinones SM, Torro CM, Saiz A et al (2014) Optic neuritis in the setting of NMDA receptor encephalitis. J Neuro-ophthalmol 34(3):316–319CrossRef
14.
ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33(5):634–643PubMedCrossRef
15.
Hanly JG (2014) Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 10(6):338–347PubMedCrossRef
16.
Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ et al (2009) AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 65(4):424–434PubMedCentralPubMedCrossRef
17.
18.
Graus F, Boronat A, Xifro X, Boix M, Svigelj V et al (2010) The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 74(10):857–859PubMedCrossRef
19.
Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L et al (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131(Pt 10):2553–2563PubMedCrossRef
20.
Mata S, Muscas GC, Naldi I, Rosati E, Paladini S et al (2008) Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 199(1–2):155–159PubMedCrossRef
21.
Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67(4):470–478PubMedCrossRef
22.
Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M et al (2007) Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 61(6):544–551PubMedCrossRef
23.
Christgau S, Aanstoot HJ, Schierbeck H, Begley K, Tullin S et al (1992) Membrane anchoring of the autoantigen GAD65 to microvesicles in pancreatic beta-cells by palmitoylation in the NH2-terminal domain. J Cell Biol 118(2):309–320PubMedCrossRef
24.
Chavez-Valdez R, Martin LJ, Flock DL, Northington FJ (2012) Necrostatin-1 attenuates mitochondrial dysfunction in neurons and astrocytes following neonatal hypoxia-ischemia. Neuroscience 219:192–203PubMedCentralPubMedCrossRef
25.
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R et al (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9(1):67–76PubMedCentralPubMedCrossRef
26.
Boronat A, Sabater L, Saiz A, Dalmau J, Graus F (2011) GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 76(9):795–800PubMedCentralPubMedCrossRef
27.
Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E et al (2014) Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 137(Pt 8):2178–2192PubMedCentralPubMedCrossRef
28.
Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T et al (2014) Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 13(3):276–286PubMedCrossRef
29.
Chang T, Alexopoulos H, McMenamin M, Carvajal-Gonzalez A, Alexander SK et al (2013) Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. JAMA Neurol 70(9):1140–1149PubMedCrossRef
30.
Meinck HM, Thompson PD (2002) Stiff man syndrome and related conditions. Mov Disord 17(5):853–866PubMedCrossRef
31.
Irani SR, Gelfand JM, Al-Diwani A, Vincent A (2014) Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol 76(2):168–184PubMedCentralPubMedCrossRef
32.
Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S et al (2008) Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 71(16):1291–1292PubMedCrossRef
33.
Damasio J, Leite MI, Coutinho E, Waters P, Woodhall M et al (2013) Progressive encephalomyelitis with rigidity and myoclonus: the first pediatric case with glycine receptor antibodies. JAMA Neurol 70(4):498–501PubMedCrossRef
34.
Turner MR, Irani SR, Leite MI, Nithi K, Vincent A et al (2011) Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology 77(5):439–443PubMedCentralPubMedCrossRef
35.
Mundiyanapurath S, Jarius S, Probst C, Stocker W, Wildemann B et al (2013) GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol 259(1–2):88–91PubMedCrossRef
36.
Kim TJ, Lee ST, Shin JW, Moon J, Lim JA et al (2014) Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. J Neuroimmunol 270(1–2):45–50PubMedCrossRef
37.
Ohkawa T, Satake S, Yokoi N, Miyazaki Y, Ohshita T et al (2014) Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. J Neurosci 34(24):8151–8163PubMedCrossRef
38.
Hart IK, Waters C, Vincent A, Newland C, Beeson D et al (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41(2):238–246PubMedCrossRef
39.
Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P et al (2012) Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 72(2):241–255PubMedCrossRef
40.
Liguori R, Vincent A, Clover L, Avoni P, Plazzi G et al (2001) Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124(Pt 12):2417–2426PubMedCrossRef
41.
Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M et al (2004) Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62(7):1177–1182PubMedCrossRef
42.
Vincent A, Buckley C, Schott JM, Baker I, Dewar BK et al (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127(Pt 3):701–712PubMed
43.
Barajas RF, Collins DE, Cha S, Geschwind MD (2010) Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia 51(3):473–477PubMedCentralPubMedCrossRef
44.
Irani SR, Michell AW, Lang B, Pettingill P, Waters P et al (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69(5):892–900PubMedCrossRef
45.
Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA et al (2013) Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136(Pt 10):3151–3162PubMedCrossRef
46.
McKnight K, Jiang Y, Hart Y, Cavey A, Wroe S et al (2005) Serum antibodies in epilepsy and seizure-associated disorders. Neurology 65(11):1730–1736PubMedCrossRef
47.
Klein CJ, Lennon VA, Aston PA, McKeon A, Pittock SJ (2012) Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 79(11):1136–1144PubMedCentralPubMedCrossRef
48.
Becker EB, Zuliani L, Pettingill R, Lang B, Waters P et al (2012) Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 83(4):437–440PubMedCentralPubMedCrossRef
49.
Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS (2006) Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 129(Pt 6):1570–1584PubMedCrossRef
50.
Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L et al (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9(8):776–785PubMedCentralPubMedCrossRef
51.
Fukata Y, Lovero KL, Iwanaga T, Watanabe A, Yokoi N et al (2010) Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Nat Acad Sci USA 107(8):3799–3804PubMedCentralPubMedCrossRef
52.
Malter MP, Frisch C, Schoene-Bake JC, Helmstaedter C, Wandinger KP et al (2014) Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol 261(9):1695–1705PubMedCrossRef
53.
Klein CJ, Lennon VA, Aston PA, McKeon A, O’Toole O et al (2013) Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 70(2):229–234PubMedCentralPubMedCrossRef
54.
Buckley C, Oger J, Clover L, Tuzun E, Carpenter K et al (2001) Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50(1):73–78PubMedCrossRef
55.
Szots M, Marton A, Kover F, Kiss T, Berki T et al (2014) Natural course of LGI1 encephalitis: 3–5 years of follow-up without immunotherapy. J Neurol Sciences 343(1–2):198–202CrossRef
56.
Shin YW, Lee ST, Shin JW, Moon J, Lim JA et al (2013) VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 265(1–2):75–81PubMedCrossRef
57.
Lilleker JB, Jones MS, Mohanraj R (2013) VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure 22(9):776–779PubMedCrossRef
58.
Plantone D, Renna R, Grossi D, Plantone F, Iorio R (2013) Teaching NeuroImages: basal ganglia involvement in facio-brachial dystonic seizures associated with LGI1 antibodies. Neurology 80(17):e183–e184PubMedCrossRef
59.
Quek AM, Britton JW, McKeon A, So E, Lennon VA et al (2012) Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 69(5):582–593PubMedCentralPubMedCrossRef
60.
Irani SR, Buckley C, Vincent A, Cockerell OC, Rudge P et al (2008) Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 71(20):1647–1648PubMedCrossRef
61.
Yoo JY, Hirsch LJ (2014) Limbic encephalitis associated with anti-voltage-gated potassium channel complex antibodies mimicking Creutzfeldt-Jakob disease. JAMA Neurol 71(1):79–82PubMedCrossRef
62.
Rocamora R, Becerra JL, Fossas P, Gomez M, Vivanco-Hidalgo RM et al (2014) Pilomotor seizures: an autonomic semiology of limbic encephalitis? Seizure 23(8):670–673PubMedCrossRef
63.
Naasan G, Irani SR, Bettcher BM, Geschwind MD, Gelfand JM (2014) Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol 71(10):1300–1304PubMedPubMedCentralCrossRef
64.
65.
Sharma S, Sharma P (2013) Morvan syndrome: after scrotal sac drainage and chemical instillation in hydrocele. Neurol India 61(3):300–302PubMedCrossRef
66.
Olberg H, Haugen M, Storstein A, Vedeler CA (2013) Neurological manifestations related to level of voltage-gated potassium channel antibodies. J Neurol Neurosurg Psychiatry 84(8):941–943PubMedCrossRef
67.
Paterson RW, Zandi MS, Armstrong R, Vincent A, Schott JM (2014) Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 85(6):625–630PubMedCentralPubMedCrossRef
68.
Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M et al (2013) Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 73(1):120–128PubMedCentralPubMedCrossRef
69.
Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL et al (2014) DPPX potassium channel antibody: Frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 83(20):1797–1803PubMedPubMedCentralCrossRef
70.
Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J et al (2014) A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13(6):575–586PubMedCentralPubMedCrossRef
71.
Angus-Leppan H, Rudge P, Mead S, Collinge J, Vincent A (2013) Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol 70(7):919–922PubMedCrossRef
72.
Rossi M, Mead S, Collinge J, Rudge P, Vincent A (2014) Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (in press)
73.
Lalic T, Pettingill P, Vincent A, Capogna M (2011) Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia 52(1):121–131PubMedCrossRef
74.
Ohkawa T, Fukata Y, Yamasaki M, Miyazaki T, Yokoi N et al (2013) Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 33(46):18161–18174PubMedCentralPubMedCrossRef
75.
Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I et al (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135(Pt 5):1622–1638PubMedCrossRef
76.
Misu T, Fujihara K, Kakita A, Konno H, Nakamura M et al (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130(Pt 5):1224–1234PubMedCrossRef
77.
Forrest D, Yuzaki M, Soares HD, Ng L, Luk DC et al (1994) Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 13(2):325–338PubMedCrossRef
78.
Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G et al (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13(1):76–83PubMedCentralPubMedCrossRef
79.
McNamara RK, Skelton RW (1996) Baclofen, a selective GABAB receptor agonist, dose-dependently impairs spatial learning in rats. Pharmacol Biochem Behav 53(2):303–308PubMedCrossRef
80.
Schuler V, Luscher C, Blanchet C, Klix N, Sansig G et al (2001) Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 31(1):47–58PubMedCrossRef
81.
Xi B, Chen J, Yang L, Wang W, Fu M et al (2011) GABBR1 gene polymorphism(G1465A)isassociated with temporal lobe epilepsy. Epilepsy Res 96(1–2):58–63PubMedCrossRef
82.
Zai G, King N, Wong GW, Barr CL, Kennedy JL (2005) Possible association between the gamma-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia. Eur Neuropsychopharmacol 15(3):347–352PubMedCrossRef
83.
Zai G, Arnold P, Burroughs E, Barr CL, Richter MA et al (2005) Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. Am J Med Genet Part B Neuropsychiatric Genet 134B(1):25–29CrossRef
84.
Yu YE, Wen L, Silva J, Li Z, Head K et al (2010) Lgi1 null mutant mice exhibit myoclonic seizures and CA1 neuronal hyperexcitability. Hum Mol Genet 19(9):1702–1711PubMedCentralPubMedCrossRef
85.
Zhou YD, Lee S, Jin Z, Wright M, Smith SE et al (2009) Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat Med 15(10):1208–1214PubMedCentralPubMedCrossRef
86.
Nobile C, Michelucci R, Andreazza S, Pasini E, Tosatto SC et al (2009) LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy. Hum Mutat 30(4):530–536PubMedCrossRef
87.
Gu W, Brodtkorb E, Steinlein OK (2002) LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol 52(3):364–367PubMedCrossRef
88.
Kinali M, Jungbluth H, Eunson LH, Sewry CA, Manzur AY et al (2004) Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia. Neuromuscul Disord 14(10):689–693PubMedCrossRef
89.
Zuberi SM, Eunson LH, Spauschus A, De Silva R, Tolmie J et al (1999) A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain 122(Pt 5):817–825PubMedCrossRef
90.
Poliak S, Salomon D, Elhanany H, Sabanay H, Kiernan B et al (2003) Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol 162(6):1149–1160PubMedCentralPubMedCrossRef
91.
Penagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A et al (2011) Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 147(1):235–246PubMedCentralPubMedCrossRef
92.
Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV et al (2008) Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 82(1):150–159PubMedCentralPubMedCrossRef
93.
Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE et al (2006) Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 354(13):1370–1377PubMedCrossRef
94.
Friedman JI, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA et al (2008) CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry 13(3):261–266PubMedCrossRef
95.
Leypoldt F, Armangue T, Dalmau J (2014) Autoimmune encephalopathies. Ann N Y Acad Sci (in press)
96.
Zandi MS, Paterson RW, Ellul MA, Jacobson L, Al-Diwani A et al. (2014) Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes. J Neurol Neurosurg Psychiatry (in press)
97.
Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L et al (2010) Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30(17):5866–5875PubMedCentralPubMedCrossRef
98.
Dahm L, Ott C, Steiner J, Stepniak B, Teegen B et al (2014) Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 76(1):82–94PubMedCrossRef
99.
Pruss H, Holtje M, Maier N, Gomez A, Buchert R et al (2012) IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 78(22):1743–1753PubMedCentralPubMedCrossRef
100.
Choe CU, Karamatskos E, Schattling B, Leypoldt F, Liuzzi G et al (2013) A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. Psychiatry Res 208(2):194–196PubMedCrossRef
101.
Armangue T, Titulaer MJ, Malaga I, Bataller L, Gabilondo I et al (2013) Pediatric anti-N-methyl-d-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 162(4):850–856PubMedCentralPubMedCrossRef
102.
Hacohen Y, Deiva K, Pettingill P, Waters P, Siddiqui A et al (2014) N-methyl-d-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 29(1):90–96PubMedCrossRef
103.
Mackay G, Ahmad K, Stone J, Sudlow C, Summers D et al (2012) NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol 259(9):1979–1981PubMedCrossRef
104.
Lachance DH, Lennon VA, Pittock SJ, Tracy JA, Krecke KN et al (2010) An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol 9(1):55–66PubMedCrossRef
105.
Meeusen JW, Klein CJ, Pirko I, Haselkorn KE, Kryzer TJ et al (2012) Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol. Ann Neurol 71(3):417–426PubMedCentralPubMedCrossRef
106.
Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474–481PubMedCentralPubMedCrossRef
107.
Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A et al (2011) Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 69(2):303–311PubMedCentralPubMedCrossRef
108.
Hoftberger R, Titulaer MJ, Sabater L, Dome B, Rozsas A et al (2013) Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 81(17):1500–1506PubMedCentralPubMedCrossRef
109.
Cree BA, Lamb S, Morgan K, Chen A, Waubant E et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7):1270–1272PubMedCrossRef
110.
Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y et al (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Multiple Scler 13(1):128–132CrossRef
111.
Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443–1448PubMedCrossRef
112.
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114PubMedCrossRef
113.
Brodtkorb E, Gu W, Nakken KO, Fischer C, Steinlein OK (2002) Familial temporal lobe epilepsy with aphasic seizures and linkage to chromosome 10q22-q24. Epilepsia 43(3):228–235PubMedCrossRef
114.
Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y et al (2011) Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 88(3):306–316PubMedCentralPubMedCrossRef
115.
Manahan-Vaughan D, von Haebler D, Winter C, Juckel G, Heinemann U (2008) A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 18(2):125–134PubMedCrossRef
116.
Curran HV, Morgan C (2000) Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 95(4):575–590PubMedCrossRef
117.
Prosser HM, Gill CH, Hirst WD, Grau E, Robbins M et al (2001) Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice. Mol Cell Neurosci 17(6):1059–1070PubMedCrossRef
118.
Wernicke C, Samochowiec J, Schmidt LG, Winterer G, Smolka M et al (2003) Polymorphisms in the N-methyl-d-aspartate receptor 1 and 2B subunits are associated with alcoholism-related traits. Biol Psychiatry 54(9):922–928PubMedCrossRef
119.
Zhao X, Li H, Shi Y, Tang R, Chen W et al (2006) Significant association between the genetic variations in the 5′ end of the N-methyl-d-aspartate receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry 59(8):747–753PubMedCrossRef
120.
Chanasong R, Thanoi S, Watiktinkorn P, Reynolds GP, Nudmamud-Thanoi S (2013) Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population. Neurosci Lett 551:58–61PubMedCrossRef
121.
Epi KC, Phenome Epilepsy, Genome P, Allen AS, Berkovic SF, Cossette P et al (2013) De novo mutations in epileptic encephalopathies. Nature 501(7466):217–221CrossRef
122.
Bennett DR, Madsen JA, Jordan WS, Wiser WC (1973) Ketamine anesthesia in brain-damaged epileptics. Electroencephalographic and clinical observations. Neurology 23(5):449–460PubMedCrossRef
123.
Badran S, Schmutz M, Olpe HR (1997) Comparative in vivo and in vitro studies with the potent GABAB receptor antagonist, CGP 56999A. Eur J Pharmacol 333(2–3):135–142PubMedCrossRef
124.
Taittonen MT, Kirvela OA, Aantaa R, Kanto JH (1998) The effect of clonidine or midazolam premedication on perioperative responses during ketamine anesthesia. Anesth Analg 87(1):161–167PubMed
125.
McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA (1981) Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 10(5):237–242PubMedCrossRef
126.
Marco LA, Joshi RS (1992) A ketamine-induced rat model of tardive dyskinesia. Prog Neurobiol 38(6):571–600PubMedCrossRef
127.
Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167(1):127–135PubMedCrossRef
Metadata
Title
Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions
Authors
James Varley
Angela Vincent
Sarosh R. Irani
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 4/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7600-8

Other articles of this Issue 4/2015

Journal of Neurology 4/2015 Go to the issue

Letter to the Editors

Role of handedness-related vestibular cortical dominance upon the vestibular–ocular reflex

Original Communication

Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study

Original Communication

Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis

Letter to the Editors

Vanishing splenial lesion presenting as alexia with dysgraphia

Original Communication

Multiple sclerosis in Japan appears to be a milder disease compared to the UK

Short Commentary

Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study